NCT05900973View on ClinicalTrials.gov

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

May 17, 2025

Study Completion Date

May 24, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Darolutamide Oral Tablet [Nubeqa]

Oral use of Darolutamide as an Inducer of Increased Expression of Prostate-specific membrane antigen (PSMA) in patients with Localized prostate cancer

Trial Locations (1)

Unknown

RECRUITING

Instituto D'Or de Pesquisa e Ensino, São Paulo

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

RPH Central Pharma

UNKNOWN

lead

D'Or Institute for Research and Education

OTHER

NCT05900973 - A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer | Biotech Hunter | Biotech Hunter